Patent intelligence · WO
WO 2013015774
DIHYDROXY-CHLORINES GLYCO-SUBSTITUÉES ET CHLORINES BÊTA-FONCTIONNALISÉES POUR THÉRAPIE ANTIMICROBIENNE PHOTODYNAMIQUE
DIHYDROXY-CHLORINES GLYCO-SUBSTITUÉES ET CHLORINES BÊTA-FONCTIONNALISÉES POUR THÉRAPIE ANTIMICROBIENNE PHOTODYNAMIQUE
Patent details — WO 2013015774
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Jan 31, 2013
- Expiration
- Jan 26, 2033
- Applicant
- BIOLITEC PHARMA MARKETING LTD [MY]
- CPC classes
- A61K 31/ 19 A I, A61K 31/ 185 A I, A61K 31/ 409 A I, A61K/31185
Quick answer
WO 2013015774 (DIHYDROXY-CHLORINES GLYCO-SUBSTITUÉES ET CHLORINES BÊTA-FONCTIONNALISÉES POUR THÉRAPIE ANTIMICROBIENNE PHOTODYNAMIQUE) is held by BIOLITEC PHARMA MARKETING LTD [MY]. Status: granted. Granted Jan 31, 2013. Expires Jan 26, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIOLITEC PHARMA MARKETING LTD [MY]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 19 A I, A61K 31/ 185 A I, A61K 31/ 409 A I, A61K/31185, A61K/3119, A61K/31409
More from BIOLITEC PHARMA MARKETING LTD [MY]
Related pharmaceutical patents in our USPTO index.
-
BR PI0714667
conjugado molecular e respectivo uso
granted -
MX 2013000877
APPLICATION OF β-FUNCTIONALIZED DIHYDROXY-CHLORINS FOR PDT.
granted -
US 2013041307
APPLICATION OF BETA-FUNCTIONALIZED DIHYDROXY-CHLORINS FOR PDT
granted -
BR PI0614453
método de redução de cululite indesejada em áreas seletivas de um organismo e mistura fotossensibilizante
granted -
US 2012263625
GLYCO-SUBSTITUTED DIHYDROXY-CHLORINS AND ß-FUNCTIONALIZED CHLORINS FOR ANTI-MICROBIAL PHOTODYNAMIC THERAPY
granted -
US 2012259187
DYNAMIC COLORECTAL PDT APPLICATION
granted -
US 2011206613
METHOD AND APPLICATION OF UNSYMMETRICALLY meso-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT
granted
Frequently asked questions
What is US patent 2013015774?
WO 2013015774 (DIHYDROXY-CHLORINES GLYCO-SUBSTITUÉES ET CHLORINES BÊTA-FONCTIONNALISÉES POUR THÉRAPIE ANTIMICROBIENNE PHOTODYNAMIQUE) is held by BIOLITEC PHARMA MARKETING LTD [MY]. Status: granted. Granted Jan 31, 2013. Expires Jan 26, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2013015774?
BIOLITEC PHARMA MARKETING LTD [MY] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does WO 2013015774 expire?
Our index shows an expiration date of Jan 26, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.